Cite
Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019).
MLA
Wang, Peng-Fei, et al. “Cyclin-Dependent Kinase 4/6 Inhibitors for Cancer Therapy: A Patent Review (2015 - 2019).” Expert Opinion on Therapeutic Patents, vol. 30, no. 10, Oct. 2020, pp. 795–805. EBSCOhost, https://doi.org/10.1080/13543776.2020.1825686.
APA
Wang, P.-F., Qiu, H.-Y., He, Y., & Zhu, H.-L. (2020). Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019). Expert Opinion on Therapeutic Patents, 30(10), 795–805. https://doi.org/10.1080/13543776.2020.1825686
Chicago
Wang, Peng-Fei, Han-Yue Qiu, Yun He, and Hai-Liang Zhu. 2020. “Cyclin-Dependent Kinase 4/6 Inhibitors for Cancer Therapy: A Patent Review (2015 - 2019).” Expert Opinion on Therapeutic Patents 30 (10): 795–805. doi:10.1080/13543776.2020.1825686.